Celltrion's Herzuma (biosimilar- trastuzumab) Overtook the Original Treatments for Cancer
Shots:
- Herzuma wins <51% of the market share in Japan in Jun’21 & secured the top position with the reliability proved by the expanding prescriptions globally. Celltrion is co-promoting Herzuma along with Nippon Kayaku
- Celltrion also mentioned the Japanese government's policy change as another factor to affect Herzuma prescription positively. Tokyo has added a policy to promote biosimilar drugs in Prime Minister Yoshihide Suga's Honbebuto Paper in Jun’21
- Celltrion has declared the bids for Herzuma & Truxima in Brazil and Japan. The company plans to launch Remsima (infliximab) & Yuflyma (adalimumab)
| Ref: Businesswire | Image: Celltrion
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
